Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | F13A1 | P00488 | 2/20 | 0.54 |
| ▸ | TGM2 | P21980 | 2/20 | 0.54 |
| ▸ | TGM1 | P22735 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14992459 | 0.91 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL3898493 | 0.88 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL77639 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL2896415 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL31460273 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL7393652 | 0.85 | MEN1 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL3970912 | 0.85 | MEN1 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL379160 | 0.85 | MEN1 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL4814264 | 0.85 | MEN1 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL2630944 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1950342-A | Novel compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2007-04-18 | — | — | CN | claimed |
| CN-103459369-B | Guanidine compound | ASTELLAS PHARMA INC | 2015-05-27 | — | — | CN | disclosed |
| US-20070185128-A1 | Compounds and compositions for treating obesity | NOVO NORDISK A/S (DK) | 2007-08-09 | — | — | US | disclosed |
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | disclosed |
| US-6518429-B2 | Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus | LG CHEMICAL, LTD. (KR) | 2003-02-11 | — | — | US | disclosed |
| US-6472526-B1 | SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES | LG CHEMICAL LTD. (KR) | 2002-10-29 | — | — | US | disclosed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | disclosed |
| US-6268363-B1 | ANTITUMOR | LG CHEMICAL LTD. (KR) | 2001-07-31 | — | — | US | disclosed |
| EP-0981526-A1 | NOVEL ANTIDIABETIC COMPOUNDS HAVING HYPOLIPIDAEMIC, ANTIHYPERTENSIVE PROPERTIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-03-01 | — | — | EP | disclosed |
| WO-1997041119-A1 | NOVEL ANTIDIABETIC COMPOUNDS HAVING HYPOLIPIDAEMIC, ANTIHYPERTENSIVE PROPERTIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185128-A1 | Compounds and compositions for treating obesity | MC4R, MC5R, MC3R | SMN1; SMN2 3649/4885NPC1 607/4885RAB9A 1725/4885 |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | FNTA, FNTB, FDPS | SMN1; SMN2 4849/4885NPC1 19/4885RAB9A 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.